# Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

> **NCT06282874** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 41 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Brain Metastases
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06282874
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-03-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06282874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06282874, "Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06282874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*